布地奈德／福莫特罗吸入剂治疗妊娠期哮喘疗效观察

目的探讨布地奈德／福莫特罗干粉吸入剂治疗妊娠期哮喘的临床效果和不良反应。方法64例妊娠期哮喘患者按疾病严重程度使用不同剂量的布地奈德／福莫特罗吸入剂，连续应用6个月以上，期间予以随访及哮喘管理，根据哮喘控制程度评分（ACT）比较应用前后疾病控制情况，观察肺功能变化及不良反应。结果根据患者ACT问卷，治疗前达到哮喘控制的患者为4．7％（3／64）、部分控制为62．5％（40／64）、未控制为32．8％（21／64）。治疗后6个月，控制、部分控制及未控制分别为48．4％（31／64）、部分控制为42．2％（27／64）、未控制为9．4％（6／64），治疗前后哮喘控制情况差异有统计学意义（Z：5．73，P〈0．05）。治疗后6个月，第一秒钟用力呼气容积占预计值百分比及最大呼气流速占预计值百分比均明显提高（均P〈0．05）。无严重并发症发生。结论布地奈德／福莫特罗干粉吸入剂对妊娠期哮喘患者具有良好的治疗效果和安全性。

The effects of budesonide/formoterol inhalant on asthma patients during pregnancy

Objective To evaluate the therapeutic effect and safety of budesonide/formoterol inhalant on asthma patients during pregnancy. Methods A total of 64 asthma patients during pregnancy were given different dose of budesonide/formoterol inhalant according to the severity of asthma. The inhalant was used more than 6 months. Meanwhile, follow-up visit and asthma management strategies were performed. Then, the asthma control situations were evaluated by ACT. The change of pulmonary function and adverse effect were observed. Results Before treatment, the conditions of 4.7 % （3/64） asthmatic patients were controlled,62.5 % （40/64） of asthmatic patients with partial con- trol, and 32.8% （21/64） patients with uncontrolled asthma evaluated by ACT. After budesonide/formoterol inhalant treatment for 6 months, asthmatic patients with control, partial control and uncontrol were 48.4% （31/64）, 42.2% （27/64） ,9.4% （6/64） , respectively, which were significantly improved than before treatment （ Z = 5.73, P 〈 0. 05 ）. Compared with pre-treatment, percentage of predicted forced expiratory volume in one second （ FEV1 pre） and peak expiratory flow rate（ PEF% pre） of post-management were significantly improved（ P 〈 0.05 ）. Few adverse effects were observed. Conclusion Budesonide/formoterol inhalant can effectively improve the asthma situations in patients during pregnancy and has favourable security.